Guidelines for screening of breast cancer in patients with mutations

BRCA1/BRCA2:
👉Age 25 to 29 – Annual breast MRI with contrast (or mammogram preferably with tomosynthesis if MRI is unavailable)
👉Age 35 to 75 – Annual mammogram preferably with tomosynthesis and breast MRI with contrast
👉Age > 75 – Management should be considered on an individual basis

TP53:
👉20 to 29 – Annual breast MRI with contrast 👉30 to 75 – Annual mammogram preferably with tomosynthesis and breast MRI with contrast
👉Age > 75 – Management should be considered on an individual basis

ATM:
👉Annual mammogram with consideration of tomosynthesis and consider breast MRI with contrast at age 40 y

CDH1:
👉Annual mammogram with consideration of tomosynthesis and consider breast MRI with contrast at age 30 y

CHEK2:
👉Annual mammogram with consideration of tomosynthesis and consider breast MRI with contrast at age 40 y

NBN:
👉Annual mammogram with consideration of tomosynthesis and consider breast MRI with contrast at age 40 y

NF1:
👉Annual mammogram with consideration of tomosynthesis at age 30 y and consider breast MRI with contrast from age 30 to 50 y

PALB2:
👉Annual mammogram with consideration of tomosynthesis and consider breast MRI with contrast at age 30 y

PTEN:
Annual mammogram with consideration of tomosynthesis and consider breast MRI with contrast at age 30 to 35 y or 5 to 10 yrs before earliest family breast cancer

STK11:
👉Annual mammogram with consideration of tomosynthesis and consider breast MRI with contrast at age 25 y

#Arrangoiz #BreastSurgeon #BreastCancer

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s